MSQ Webinar: Unveiling What's New, Expert Insights and Partnership Opportunities in Targeted Protein Degradation (TPD)
Part 2 on AUGUST 24, 2023
In the surge of TPD drug development, we are excited to invite you to join our upcoming MSQ Webinar together with MNCs who heavily invest in TPD, emerging TPD global players and dealmakers, co-hosted by MSQ Ventures and BioAroundWorld. The discussion will cover the latest breakthrough and trends in this rapidly evolving space and offer insights into how to leverage partnership to monetize the pipeline and achieve greater success together.
Unveiling What's New, Expert Insights and Partnership Opportunities in Targeted Protein Degradation – PART 2
DATE: August 24th, 2023
TIME: 9:00 – 10:00 AM EST / 9:00 – 10:00 PM BJT
Moderator: Echo Hindle-Yang, President & CEO, MSQ Ventures
Speakers:
Nikhil Mutyal, Executive Director, BD&L, Merck
Randy Teel, SVP of corporate and BD, Arvinas
Lily Zou, CEO, Degron Therapeutics
Sahm Nasseri, CBO, Biotheryx
Key Highlights:
Sharing by Nikhil Mutyal, Executive Director, BD&L of Merck on global TPD partnership opportunities, and the $1 billion early discovery and development deal with Amphista TherapeuticsTechnology highlights and Company presentations of emerging TPD stars - including Arvinas, Degron Therapeutics, Biotheryx
Highlight emerging deal structures, ‘platform collaboration’ vs. ‘licensing as partnership’ strategies, and collaborations beyond oncology
Testimonial sharing by MSQ Ventures on cross-border transactions including licensing, M&A, fundraising, joint ventures and other strategic partnerships.
Can’t attend live? Register anyway, and we’ll send you the session recording after the event. Following the webinar, attendees will also have the chance to schedule a one-on-one session with BiOneCure through MSQ.